 Stage IIB osteogenic sarcoma seventy-one consecutive patients long-term survival Disease-free survival entire cohort years years Humeral lesions probability survival years tibial lesions femoral lesions Histologic response preoperative chemotherapy predictor outcome little response survival estimate ten years partial responders complete responders Local recurrence adverse effect survival patients local recurrence long-term disease-free survivors